ABBV CLS 484
Alternative Names: ABBV-CLS-484; AC-484Latest Information Update: 01 Jul 2025
At a glance
- Originator Calico
- Developer AbbVie; Calico
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists; Protein tyrosine phosphatase non-receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Acute myeloid leukaemia; Anaplastic large cell lymphoma
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 07 Dec 2024 Preclinical trials in Anaplastic large cell lymphoma in USA (unspecified route) before December 2024
- 07 Dec 2024 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to December 2024